

Frederic Jaisser

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1941022/publications.pdf>

Version: 2024-02-01

160
papers

8,583
citations

34076

52
h-index

54882

84
g-index

166
all docs

166
docs citations

166
times ranked

8718
citing authors

#	ARTICLE	IF	CITATIONS
1	Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis. Progress in Retinal and Eye Research, 2015, 48, 82-118.	7.3	712
2	Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. Journal of Clinical Investigation, 2012, 122, 2672-2679.	3.9	316
3	Myocardial fibrosis: biomedical research from bench to bedside. European Journal of Heart Failure, 2017, 19, 177-191.	2.9	280
4	Conditional Mineralocorticoid Receptor Expression in the Heart Leads to Life-Threatening Arrhythmias. Circulation, 2005, 111, 3025-3033.	1.6	240
5	Mineralocorticoid Receptor Activation and Mineralocorticoid Receptor Antagonist Treatment in Cardiac and Renal Diseases. Hypertension, 2015, 65, 257-263.	1.3	169
6	Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. European Heart Journal, 2014, 35, 932-941.	1.0	167
7	Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis. Kidney International, 2019, 96, 302-319.	2.6	145
8	In Vivo, Villin Is Required for Ca ²⁺ -Dependent F-Actin Disruption in Intestinal Brush Borders. Journal of Cell Biology, 1999, 146, 819-830.	2.3	139
9	The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure. FASEB Journal, 2010, 24, 2454-2463.	0.2	135
10	Role of β -Subunit Domains in the Assembly, Stable Expression, Intracellular Routing, and Functional Properties of Na,K-ATPase. Journal of Biological Chemistry, 1998, 273, 30826-30835.	1.6	131
11	Characterization of Rat NDRG2 (N-Myc Downstream Regulated Gene 2), a Novel Early Mineralocorticoid-specific Induced Gene. Journal of Biological Chemistry, 2002, 277, 31506-31515.	1.6	131
12	The neuroretina is a novel mineralocorticoid target: aldosterone upregulates ion and water channels in Müller glial cells. FASEB Journal, 2010, 24, 3405-3415.	0.2	129
13	Galectin-3 Blockade Inhibits Cardiac Inflammation and Fibrosis in Experimental Hyperaldosteronism and Hypertension. Hypertension, 2015, 66, 767-775.	1.3	129
14	Modulation of the Na,K-pump function by beta subunit isoforms.. Journal of General Physiology, 1994, 103, 605-623.	0.9	128
15	Regulatory Sequences of the Mouse Villin Gene That Efficiently Drive Transgenic Expression in Immature and Differentiated Epithelial Cells of Small and Large Intestines. Journal of Biological Chemistry, 1999, 274, 6476-6482.	1.6	128
16	Searching for new mechanisms of myocardial fibrosis with diagnostic and/or therapeutic potential. European Journal of Heart Failure, 2015, 17, 764-771.	2.9	109
17	The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling. Kidney International, 2018, 93, 1344-1355.	2.6	109
18	Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. Kidney International, 2011, 79, 1051-1060.	2.6	107

#	ARTICLE	IF	CITATIONS
19	Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside. Handbook of Experimental Pharmacology, 2016, 243, 271-305.	0.9	102
20	Aldosterone, mineralocorticoid receptor, and heart failure. Molecular and Cellular Endocrinology, 2012, 350, 266-272.	1.6	100
21	More than a simple biomarker: the role of NGAL in cardiovascular and renal diseases. Clinical Science, 2018, 132, 909-923.	1.8	98
22	Smooth Muscle Cell Mineralocorticoid Receptors Are Mandatory for Aldosteroneâ€™Salt to Induce Vascular Stiffness. Hypertension, 2014, 63, 520-526.	1.3	97
23	Blood pressure and amiloride-sensitive sodium channels in vascular and renal cells. Nature Reviews Nephrology, 2014, 10, 146-157.	4.1	97
24	Epithelial Sodium Channel Stiffens the Vascular Endothelium In Vitro and in Liddle Mice. Hypertension, 2013, 61, 1053-1059.	1.3	96
25	Reversible cardiac fibrosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 7160-7165.	3.3	93
26	Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injuryâ€™Mediated Chronic Kidney Disease. Hypertension, 2017, 69, 870-878.	1.3	92
27	Adipocyte Mineralocorticoid Receptor Activation Leads to Metabolic Syndrome and Induction of Prostaglandin D2 Synthase. Hypertension, 2015, 66, 149-157.	1.3	91
28	Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets. Diabetes, Obesity and Metabolism, 2020, 22, 16-31.	2.2	91
29	Mineralocorticoid Modulation of Cardiac Ryanodine Receptor Activity Is Associated With Downregulation of FK506-Binding Proteins. Circulation, 2009, 119, 2179-2187.	1.6	88
30	Mineralocorticoid receptor antagonists in diabetic kidney disease â€™ mechanistic and therapeutic effects. Nature Reviews Nephrology, 2022, 18, 56-70.	4.1	87
31	Extrarenal effects of aldosterone. Current Opinion in Nephrology and Hypertension, 2012, 21, 147-156.	1.0	86
32	Endothelial Mineralocorticoid Receptors Differentially Contribute to Coronary and Mesenteric Vascular Function Without Modulating Blood Pressure. Hypertension, 2015, 66, 988-997.	1.3	84
33	Mineralocorticoid Receptor and Cardiovascular Disease. American Journal of Hypertension, 2018, 31, 1165-1174.	1.0	80
34	Role of the transmembrane and extracytoplasmic domain of beta subunits in subunit assembly, intracellular transport, and functional expression of Na,K-pumps.. Journal of Cell Biology, 1993, 123, 1751-1759.	2.3	79
35	CT-1 (Cardiotrophin-1)-Gal-3 (Galectin-3) Axis in Cardiac Fibrosis and Inflammation. Hypertension, 2019, 73, 602-611.	1.3	78
36	Mechanisms of urinary K+ and H+ excretion: primary structure and functional expression of a novel H,K-ATPase.. Journal of Cell Biology, 1993, 123, 1421-1429.	2.3	77

#	ARTICLE	IF	CITATIONS
37	Does the colonic H,K-ATPase also act as an Na,K-ATPase?. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 6516-6520.	3.3	76
38	Cross-Talk Between Mineralocorticoid and Angiotensin II Signaling for Cardiac Remodeling. Hypertension, 2008, 52, 1060-1067.	1.3	75
39	Neutrophil Gelatinase-Associated Lipocalin, a Novel Mineralocorticoid Biotarget, Mediates Vascular Profibrotic Effects of Mineralocorticoids. Hypertension, 2015, 66, 158-166.	1.3	75
40	Cardiomyocyte Overexpression of Neuronal Nitric Oxide Synthase Delays Transition Toward Heart Failure in Response to Pressure Overload by Preserving Calcium Cycling. Circulation, 2008, 117, 3187-3198.	1.6	73
41	Neutrophil Gelatinase-Associated Lipocalin Is a Novel Mineralocorticoid Target in the Cardiovascular System. Hypertension, 2012, 59, 966-972.	1.3	73
42	Aldosterone-Specific Activation of Cardiomyocyte Mineralocorticoid Receptor In Vivo. Hypertension, 2013, 61, 361-367.	1.3	70
43	Targeted Skin Overexpression of the Mineralocorticoid Receptor in Mice Causes Epidermal Atrophy, Premature Skin Barrier Formation, Eye Abnormalities, and Alopecia. American Journal of Pathology, 2007, 171, 846-860.	1.9	69
44	Vascular Smooth Muscle Mineralocorticoid Receptor Contributes to Coronary and Left Ventricular Dysfunction After Myocardial Infarction. Hypertension, 2016, 67, 717-723.	1.3	69
45	Benefit of Mineralocorticoid Receptor Antagonism in AKI: Role of Vascular Smooth Muscle Rac1. Journal of the American Society of Nephrology: JASN, 2017, 28, 1216-1226.	3.0	68
46	Inducible Gene Expression and Gene Modification in Transgenic Mice. Journal of the American Society of Nephrology: JASN, 2000, 11, S95-S100.	3.0	68
47	Aldosterone Target NGAL (Neutrophil Gelatinase-Associated Lipocalin) Is Involved in Cardiac Remodeling After Myocardial Infarction Through NF- κ B Pathway. Hypertension, 2017, 70, 1148-1156.	1.3	67
48	Early nongenomic events in aldosterone action in renal collecting duct cells: PKC α activation, mineralocorticoid receptor phosphorylation, and cross-talk with the genomic response. Journal of the American Society of Nephrology: JASN, 2004, 15, 1145-60.	3.0	67
49	Differential Regulations of AQP4 and Kir4.1 by Triamcinolone Acetonide and Dexamethasone in the Healthy and Inflamed Retina. , 2011, 52, 6340.		63
50	Epithelial Sodium Channel in Aldosterone-Induced Endothelium Stiffness and Aortic Dysfunction. Hypertension, 2018, 72, 731-738.	1.3	61
51	Tamoxifen administration routes and dosage for inducible Cre-mediated gene disruption in mouse hearts. Transgenic Research, 2010, 19, 715-725.	1.3	60
52	A direct relationship between plasma aldosterone and cardiac L-type Ca ²⁺ -current in mice. Journal of Physiology, 2005, 569, 153-162.	1.3	58
53	Conditional FKBP12.6 Overexpression in Mouse Cardiac Myocytes Prevents Triggered Ventricular Tachycardia Through Specific Alterations in Excitation- Contraction Coupling. Circulation, 2008, 117, 1778-1786.	1.6	57
54	Conditional glucocorticoid receptor expression in the heart induces atrioventricular block. FASEB Journal, 2007, 21, 3133-3141.	0.2	53

#	ARTICLE	IF	CITATIONS
55	Cnksr3 is a direct mineralocorticoid receptor target gene and plays a key role in the regulation of the epithelial sodium channel. <i>FASEB Journal</i> , 2009, 23, 3936-3946.	0.2	53
56	Circulating Osteoglycin and NGAL/MMP9 Complex Concentrations Predict 1-Year Major Adverse Cardiovascular Events After Coronary Angiography. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 1078-1084.	1.1	53
57	Deletion of mineralocorticoid receptors in smooth muscle cells blunts renal vascular resistance following acute cyclosporine administration. <i>Kidney International</i> , 2016, 89, 354-362.	2.6	52
58	Cardiomyocyte-specific Estrogen Receptor Alpha Increases Angiogenesis, Lymphangiogenesis and Reduces Fibrosis in the Female Mouse Heart Post-Myocardial Infarction. <i>Journal of Cell Science & Therapy</i> , 2014, 05, 153.	0.3	51
59	Molecular Signature of Mineralocorticoid Receptor Signaling in Cardiomyocytes: From Cultured Cells to Mouse Heart. <i>Endocrinology</i> , 2010, 151, 4467-4476.	1.4	50
60	Sulfenic Acid Modification of Endothelin B Receptor is Responsible for the Benefit of a Nonsteroidal Mineralocorticoid Receptor Antagonist in Renal Ischemia. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 398-404.	3.0	50
61	Neutrophil Gelatinase-Associated Lipocalin from immune cells is mandatory for aldosterone-induced cardiac remodeling and inflammation. <i>Journal of Molecular and Cellular Cardiology</i> , 2018, 115, 32-38.	0.9	47
62	Mineralocorticoid receptor antagonism limits experimental choroidal neovascularization and structural changes associated with neovascular age-related macular degeneration. <i>Nature Communications</i> , 2019, 10, 369.	5.8	47
63	The endothelial $\hat{1}\pm$ ENaC contributes to vascular endothelial function in vivo. <i>PLoS ONE</i> , 2017, 12, e0185319.	1.1	47
64	The mineralocorticoid receptor as a novel player in skin biology: beyond the renal horizon?. <i>Experimental Dermatology</i> , 2010, 19, 100-107.	1.4	46
65	Coronary endothelial dysfunction after cardiomyocyte-specific mineralocorticoid receptor overexpression. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011, 300, H2035-H2043.	1.5	46
66	Adipocyte-Specific Mineralocorticoid Receptor Overexpression in Mice Is Associated With Metabolic Syndrome and Vascular Dysfunction: Role of Redox-Sensitive PKG-1 and Rho Kinase. <i>Diabetes</i> , 2016, 65, 2392-2403.	0.3	46
67	Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion. <i>PLoS ONE</i> , 2018, 13, e0193380.	1.1	46
68	MR (Mineralocorticoid Receptor) Induces Adipose Tissue Senescence and Mitochondrial Dysfunction Leading to Vascular Dysfunction in Obesity. <i>Hypertension</i> , 2019, 73, 458-468.	1.3	46
69	Cardiomyocyte-specific overexpression of oestrogen receptor $\hat{1}^2$ improves survival and cardiac function after myocardial infarction in female and male mice. <i>Clinical Science</i> , 2016, 130, 365-376.	1.8	44
70	Topical Mineralocorticoid Receptor Blockade Limits Glucocorticoid-Induced Epidermal Atrophy in Human Skin. <i>Journal of Investigative Dermatology</i> , 2015, 135, 1781-1789.	0.3	40
71	Epithelial sodium channels in endothelial cells mediate diet-induced endothelium stiffness and impaired vascular relaxation in obese female mice. <i>Metabolism: Clinical and Experimental</i> , 2019, 99, 57-66.	1.5	40
72	Cutaneous Wound Healing in Diabetic Mice Is Improved by Topical Mineralocorticoid Receptor Blockade. <i>Journal of Investigative Dermatology</i> , 2020, 140, 223-234.e7.	0.3	40

#	ARTICLE	IF	CITATIONS
73	Nanostructured Dense Collagen-Polyester Composite Hydrogels as Amphiphilic Platforms for Drug Delivery. <i>Advanced Science</i> , 2021, 8, 2004213.	5.6	40
74	Molecular Consequences of a Frameshifted DLX3 Mutant Leading to Tricho-Dento-Osseous Syndrome. <i>Journal of Biological Chemistry</i> , 2008, 283, 20198-20208.	1.6	39
75	Epidermal Growth Factor Receptor Mediates the Vascular Dysfunction But Not the Remodeling Induced by Aldosterone/Salt. <i>Hypertension</i> , 2011, 57, 238-244.	1.3	39
76	Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2399-2407.	2.2	36
77	Myocardial Injury After Ischemia/Reperfusion Is Attenuated By Pharmacological Galectin-3 Inhibition. <i>Scientific Reports</i> , 2019, 9, 9607.	1.6	35
78	Mild ischemic Injury Leads to Long-Term Alterations in the Kidney: Amelioration by Spironolactone Administration. <i>International Journal of Biological Sciences</i> , 2015, 11, 892-900.	2.6	34
79	Aldosterone and Vascular Mineralocorticoid Receptors. <i>Hypertension</i> , 2014, 63, 632-637.	1.3	33
80	Porcine model of progressive cardiac hypertrophy and fibrosis with secondary postcapillary pulmonary hypertension. <i>Journal of Translational Medicine</i> , 2017, 15, 202.	1.8	33
81	The Mineralocorticoid Receptor Is a Constitutive Nuclear Factor in Cardiomyocytes due to Hyperactive Nuclear Localization Signals. <i>Endocrinology</i> , 2010, 151, 3888-3899.	1.4	32
82	Vascular dysfunction in obese diabetic db/db mice involves the interplay between aldosterone/mineralocorticoid receptor and Rho kinase signaling. <i>Scientific Reports</i> , 2018, 8, 2952.	1.6	32
83	Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice. <i>Journal of Molecular and Cellular Cardiology</i> , 2018, 121, 124-133.	0.9	32
84	The Diuretic Torasemide Does Not Prevent Aldosterone-Mediated Mineralocorticoid Receptor Activation in Cardiomyocytes. <i>PLoS ONE</i> , 2013, 8, e73737.	1.1	32
85	Re-Epithelialization of Pathological Cutaneous Wounds Is Improved by Local Mineralocorticoid Receptor Antagonism. <i>Journal of Investigative Dermatology</i> , 2016, 136, 2080-2089.	0.3	31
86	Roles of Mineralocorticoid Receptors in Cardiovascular and Cardioresenal Diseases. <i>Annual Review of Physiology</i> , 2022, 84, 585-610.	5.6	31
87	Aldosterone and Vascular Mineralocorticoid Receptors in Murine Endotoxic and Human Septic Shock*. <i>Critical Care Medicine</i> , 2017, 45, e954-e962.	0.4	30
88	The Aldosterone-Mineralocorticoid Receptor Pathway Exerts Anti-Inflammatory Effects in Endotoxin-Induced Uveitis. <i>PLoS ONE</i> , 2012, 7, e49036.	1.1	30
89	Differential Proteomics Identifies Reticulocalbin-3 as a Novel Negative Mediator of Collagen Production in Human Cardiac Fibroblasts. <i>Scientific Reports</i> , 2017, 7, 12192.	1.6	29
90	The Deletion of Endothelial Sodium Channel β_1 (β_1 ENaC) Impairs Endothelium-Dependent Vasodilation and Endothelial Barrier Integrity in Endotoxemia in Vivo. <i>Frontiers in Pharmacology</i> , 2018, 9, 178.	1.6	29

#	ARTICLE	IF	CITATIONS
91	Role of the vascular endothelial sodium channel activation in the genesis of pathologically increased cardiovascular stiffness. <i>Cardiovascular Research</i> , 2022, 118, 130-140.	1.8	29
92	Conditional Transgenic Mice for Studying the Role of the Glucocorticoid Receptor in the Renal Collecting Duct. <i>Endocrinology</i> , 2009, 150, 2202-2210.	1.4	28
93	The epithelial Na ⁺ channel. <i>Current Opinion in Nephrology and Hypertension</i> , 2014, 23, 143-148.	1.0	27
94	Interleukin-33/ST2 system attenuates aldosterone-induced adipogenesis and inflammation. <i>Molecular and Cellular Endocrinology</i> , 2015, 411, 20-27.	1.6	26
95	Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 1141-1157.	1.9	26
96	Novel Transgenic Mice for Inducible Gene Overexpression in Pancreatic Cells Define Glucocorticoid Receptor-Mediated Regulations of Beta Cells. <i>PLoS ONE</i> , 2012, 7, e30210.	1.1	25
97	Endothelial mineralocorticoid receptor activation enhances endothelial protein C receptor and decreases vascular thrombosis in mice. <i>FASEB Journal</i> , 2014, 28, 2062-2072.	0.2	25
98	Effect of acute and chronic aldosterone exposure on the retinal pigment epithelium-choroid complex in rodents. <i>Experimental Eye Research</i> , 2019, 187, 107747.	1.2	25
99	New roles of aldosterone and mineralocorticoid receptors in cardiovascular disease: translational and sex-specific effects. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2018, 315, H989-H999.	1.5	23
100	Dendritic cells are crucial for cardiovascular remodeling and modulate neutrophil gelatinase-associated lipocalin expression upon mineralocorticoid receptor activation. <i>Journal of Hypertension</i> , 2019, 37, 1482-1492.	0.3	23
101	Histone Deacetylase 6 Controlled Hsp90 Acetylation Significantly Alters Mineralocorticoid Receptor Subcellular Dynamics But Not its Transcriptional Activity. <i>Endocrinology</i> , 2016, 157, 2515-2532.	1.4	22
102	Aldosterone Impairs Mitochondrial Function in Human Cardiac Fibroblasts via A-Kinase Anchor Protein 12. <i>Scientific Reports</i> , 2018, 8, 6801.	1.6	22
103	Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis. <i>ESC Heart Failure</i> , 2018, 5, 139-148.	1.4	21
104	The Mineralocorticoid Receptor in Heart. <i>Hypertension</i> , 2011, 57, 679-680.	1.3	20
105	Role of smooth muscle cell mineralocorticoid receptor in vascular tone. <i>Pflugers Archiv European Journal of Physiology</i> , 2015, 467, 1643-1650.	1.3	20
106	Beneficial Effects of Mineralocorticoid Receptor Pathway Blockade against Endothelial Inflammation Induced by SARS-CoV-2 Spike Protein. <i>Biomedicines</i> , 2021, 9, 639.	1.4	20
107	Vascular mineralocorticoid receptor and blood pressure regulation. <i>Current Opinion in Pharmacology</i> , 2015, 21, 138-144.	1.7	19
108	Safety of Eplerenone for Kidney-Transplant Recipients with Impaired Renal Function and Receiving Cyclosporine A. <i>PLoS ONE</i> , 2016, 11, e0153635.	1.1	19

#	ARTICLE	IF	CITATIONS
109	Mineralocorticoid receptor and cardiac arrhythmia. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2013, 40, 910-915.	0.9	18
110	Endothelial Cell Mineralocorticoid Receptors. <i>Hypertension</i> , 2014, 63, 915-917.	1.3	17
111	The Absence of Endothelial Sodium Channel β_1 (β_1 ENaC) Reduces Renal Ischemia/Reperfusion Injury. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3132.	1.8	17
112	A New Role for the Aldosterone/Mineralocorticoid Receptor Pathway in the Development of Mitral Valve Prolapse. <i>Circulation Research</i> , 2020, 127, e80-e93.	2.0	17
113	Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice. <i>ESC Heart Failure</i> , 2021, 8, 1933-1943.	1.4	17
114	Conditional gene expression in renal collecting duct epithelial cells: use of the inducible Cre-lox system. <i>American Journal of Physiology - Renal Physiology</i> , 2004, 286, F180-F187.	1.3	17
115	Cardiomyopathy and Response to Enzyme Replacement Therapy in a Male Mouse Model for Fabry Disease. <i>PLoS ONE</i> , 2012, 7, e33743.	1.1	16
116	Nonepithelial mineralocorticoid receptor activation as a determinant of kidney disease. <i>Kidney International Supplements</i> , 2022, 12, 12-18.	4.6	16
117	The Epidermal Growth Factor Receptor Is Involved in Angiotensin II But Not Aldosterone/Salt-Induced Cardiac Remodelling. <i>PLoS ONE</i> , 2012, 7, e30156.	1.1	15
118	Aldosterone Promotes Cardiac Endothelial Cell Proliferation In Vivo. <i>Journal of the American Heart Association</i> , 2015, 4, e001266.	1.6	15
119	Vascular mineralocorticoid receptor activation and disease. <i>Experimental Eye Research</i> , 2019, 188, 107796.	1.2	15
120	11 β -HSD2 SUMOylation Modulates Cortisol-Induced Mineralocorticoid Receptor Nuclear Translocation Independently of Effects on Transactivation. <i>Endocrinology</i> , 2017, 158, 4047-4063.	1.4	14
121	Cardiac expression of neutrophil gelatinase-associated lipocalin in a model of cancer cachexia-induced cardiomyopathy. <i>ESC Heart Failure</i> , 2019, 6, 89-97.	1.4	14
122	Minor role of mature adipocyte mineralocorticoid receptor in high-fat diet-induced obesity. <i>Journal of Endocrinology</i> , 2018, 239, 229-240.	1.2	13
123	Endothelial sodium channel activation promotes cardiac stiffness and diastolic dysfunction in Western diet fed female mice. <i>Metabolism: Clinical and Experimental</i> , 2020, 109, 154223.	1.5	13
124	Western diet induces renal artery endothelial stiffening that is dependent on the epithelial $\text{Na}^+\text{Ca}^{2+}$ channel. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, F1220-F1228.	1.3	13
125	The Non-Steroidal Mineralocorticoid Receptor Antagonist KBP-5074 Limits Albuminuria and has Improved Therapeutic Index Compared With Eplerenone in a Rat Model With Mineralocorticoid-Induced Renal Injury. <i>Frontiers in Pharmacology</i> , 2021, 12, 604928.	1.6	13
126	The mineralocorticoid receptor in chronic kidney disease. <i>British Journal of Pharmacology</i> , 2022, 179, 3152-3164.	2.7	13

#	ARTICLE	IF	CITATIONS
127	Neutrophil Gelatinase-Associated Lipocalin From Macrophages Plays a Critical Role in Renal Fibrosis Via the CCL5 (Chemokine Ligand 5)-Th2 Cells-IL4 (Interleukin 4) Pathway. <i>Hypertension</i> , 2022, 79, 352-364.	1.3	13
128	Mineralocorticoid receptor modulators: a patent review (2007 – 2012). <i>Expert Opinion on Therapeutic Patents</i> , 2014, 24, 177-183.	2.4	12
129	Simultaneous Characterization of Metabolic, Cardiac, Vascular and Renal Phenotypes of Lean and Obese SHHF Rats. <i>PLoS ONE</i> , 2014, 9, e96452.	1.1	11
130	Emerging therapeutic strategies for transplantation-induced acute kidney injury: protecting the organelles and the vascular bed. <i>Expert Opinion on Therapeutic Targets</i> , 2019, 23, 495-509.	1.5	11
131	Antifibrotic effect of novel neutrophil gelatinase-associated lipocalin inhibitors in cardiac and renal disease models. <i>Scientific Reports</i> , 2021, 11, 2591.	1.6	11
132	EPURE Transplant (Eplerenone in Patients Undergoing Renal Transplant) study: study protocol for a randomized controlled trial. <i>Trials</i> , 2018, 19, 595.	0.7	10
133	Beneficial Effects of Mineralocorticoid Receptor Antagonism on Myocardial Fibrosis in an Experimental Model of the Myxomatous Degeneration of the Mitral Valve. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5372.	1.8	10
134	Transgenic Models in Renal Tubular Physiology. <i>Nephron Experimental Nephrology</i> , 1998, 6, 438-446.	2.4	9
135	Tetracycline-inducible gene expression in cultured rat renal CD cells and in intact CD from transgenic mice. <i>American Journal of Physiology - Renal Physiology</i> , 2001, 281, F1164-F1172.	1.3	9
136	Aldosterone and the mineralocorticoid receptor. <i>European Heart Journal Supplements</i> , 2011, 13, B4-B9.	0.0	9
137	Differential proteomics reveals S100-A11 as a key factor in aldosterone-induced collagen expression in human cardiac fibroblasts. <i>Journal of Proteomics</i> , 2017, 166, 93-100.	1.2	9
138	Mineralocorticoid Receptor Antagonism Prevents the Synergistic Effect of Metabolic Challenge and Chronic Kidney Disease on Renal Fibrosis and Inflammation in Mice. <i>Frontiers in Physiology</i> , 2022, 13, 859812.	1.3	9
139	Mineralocorticoid receptor antagonists in kidney transplantation: time to consider?. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 2080-2091.	0.4	8
140	Adipocyte-Mineralocorticoid Receptor Alters Mitochondrial Quality Control Leading to Mitochondrial Dysfunction and Senescence of Visceral Adipose Tissue. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2881.	1.8	8
141	Chronic Systemic Dexamethasone Regulates the Mineralocorticoid/Glucocorticoid Pathways Balance in Rat Ocular Tissues. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1278.	1.8	8
142	Sex-Related Signaling of Aldosterone/Mineralocorticoid Receptor Pathway in Calcific Aortic Stenosis. <i>Hypertension</i> , 2022, 79, 1724-1737.	1.3	8
143	Development of a targeted transgenesis strategy in highly differentiated cells: a powerful tool for functional genomic analysis. <i>Journal of Biotechnology</i> , 2005, 116, 145-151.	1.9	7
144	Mineralocorticoid Receptor Antagonism: A Promising Therapeutic Approach to Treat Ischemic AKI. <i>Nephron</i> , 2016, 134, 10-13.	0.9	7

#	ARTICLE	IF	CITATIONS
145	Vascular and inflammatory mineralocorticoid receptors in kidney disease. <i>Acta Physiologica</i> , 2020, 228, e13390.	1.8	7
146	Endothelial sodium channel activation mediates DOCA-salt-induced endothelial cell and arterial stiffening. <i>Metabolism: Clinical and Experimental</i> , 2022, 130, 155165.	1.5	7
147	Chapter 4 Structureâ€œFunction Relationship of Na,K-ATPase: The Digitalis Receptor. <i>Current Topics in Membranes</i> , 1994, 41, 71-85.	0.5	6
148	Pathophysiological role of the mineralocorticoid receptor in heart: analysis of conditional transgenic models. <i>Pflugers Archiv European Journal of Physiology</i> , 2003, 445, 477-481.	1.3	6
149	Targeting the aldosterone pathway in cardiovascular disease. <i>Fundamental and Clinical Pharmacology</i> , 2012, 26, 135-145.	1.0	6
150	The Mineralocorticoid Receptor Antagonist Eplerenone Suppresses Interstitial Fibrosis in Subcutaneous Adipose Tissue in Patients With Type 2 Diabetes. <i>Diabetes</i> , 2021, 70, 196-203.	0.3	6
151	The non-steroidal mineralocorticoid receptor antagonist finerenone is a novel therapeutic option for patients with Type 2 diabetes and chronic kidney disease. <i>Clinical Science</i> , 2022, 136, 1005-1017.	1.8	5
152	Aldosterone/Mineralocorticoid Receptor Downstream Targets as Novel Therapeutic Targets to Prevent Cardiovascular Remodeling. , 0, , .		2
153	MR (Mineralocorticoid Receptor) in Endothelial Cells: A Major Contributor in Pulmonary Arterial Hypertension Remodeling. <i>Hypertension</i> , 2021, 78, 466-468.	1.3	2
154	Biglycan Is a Novel Mineralocorticoid Receptor Target Involved in Aldosterone/Salt-Induced Glomerular Injury. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6680.	1.8	2
155	Mineralocorticoid receptor antagonists: a patent evaluation of US20150284376A1. <i>Expert Opinion on Therapeutic Patents</i> , 2016, 26, 1111-1114.	2.4	1
156	Editorial: Kidney and Distant Organ Crosstalk in Health and Disease. <i>Frontiers in Physiology</i> , 2021, 12, 712535.	1.3	1
157	Letter to the Editor From Behar-Cohen et al.: â€œThe Cortisol Response of Male and Female Choroidal Endothelial Cells: Implications for Central Serous Chorioretinopathyâ€œ. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, , .	1.8	1
158	Conditional Fkbp12.6 overexpression in mouse cardiac myocytes protects from triggered ventricular arrhythmia. <i>Journal of Molecular and Cellular Cardiology</i> , 2007, 42, S3-S4.	0.9	0
159	369 VASCULAR EFFECTS OF ALDOSTERONE. <i>Journal of Hypertension</i> , 2012, 30, e108.	0.3	0
160	Potential Benefit of Mineralocorticoid Receptor Antagonists in Kidney Diseases. , 0, , .		0